MIST Milestone Pharmaceuticals Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$1.23

Period return

-0.76 (-38.19%)

Volume

456.1K

2026-07-21O $1.17 H $1.23 L $1.17 C $1.23MA5 $1.22MA20 $1.27MA60 $1.45MA120 $1.58

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 12.Highin 22 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 14.LowBUY2 months ago
Wells Fargo: Overweight
US analyst rating / recommendation change.
2026. 01. 07.LowBUY7 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 12. 17.LowBUY7 months ago
Wells Fargo: Overweight
US analyst rating / recommendation change.
2025. 12. 16.MediumBUY7 months ago
TD Cowen: Buy
US analyst rating / recommendation change.
2025. 12. 16.LowBUY7 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 09. 11.MediumBUY10 months ago
Wells Fargo: Overweight
US analyst rating / recommendation change.
2025. 04. 02.LowBUYlast year
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 03. 31.Mediumlast year
2026년 1분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2025. 03. 29.LowBUYlast year
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $6.33 · 6 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.

Sector: Healthcare
Industry: Biotechnology
HQ: Montreal, QC, Canada
Fiscal year end: —
Employees: 38
IPO date: —

View details →

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 12.	After market close (AMC)	$-0.19	—	—	$1.1M	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$-0.31	—	—	$0	Reported

Milestone Pharmaceuticals Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 14.	Wells Fargo	—	Maintain	Overweight → Overweight	—	Wells Fargo: Overweight
2026. 01. 07.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2025. 12. 17.	Wells Fargo	—	Maintain	Overweight → Overweight	—	Wells Fargo: Overweight
2025. 12. 16.	TD Cowen	—	Upgrade	Hold → Buy	—	TD Cowen: Hold → Buy
2025. 12. 16.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2025. 09. 11.	Wells Fargo	—	Initiate coverage	— → Overweight	—	Wells Fargo: Overweight